Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1209 injection site comparison in healthy volunteers
NCT05370950Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of recaticimab in hypercholesterolemia and hyperlipidemia (3 arms), sponsored by Hengrui. Primary endpoints: Area Under the Curve from time zero to last quantifiable concentration at 113 days, Area Under the Curve from time zero to infinity at 113 days and 1 more. Started May 2022; status: completed.
02
Drugs
recaticimab
03
Conditions
hypercholesterolemiahyperlipidemia
Beyond the preview
Go deeper on NCT05370950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05370950.